• OncologyTube Cancer Articles, News and Videos

      Site: OncologyTube Cancer Articles, News and Videos

    • Search in
    • Categories
    • Tags
    • Date within
    • Views
    • 0
      • Portuguese
      • Spanish
      • Italian
      • Greek (Greece)
      • Sinhala
      • Polish
      • Arabic (Saudi Arabia)
      • Swedish (Sweden)
      • Portuguese (Brazil)
      • Hindi (India)
      • English (Australia)
      • Hebrew (Israel)
      • Czech
      • Hungarian (Hungary)
      • Chinese
      • Turkish
      • Japanese (Japan)
      • Dutch
      • French
      • German
      • Chinese (Traditional Han, Taiwan)
      • Korean (South Korea)
      • Thai
      • Spanish (Chile)
      • English (United States)
      • Russian
      • Danish (Denmark)
  • Home
  • Trending

  • Login

  • Quick Links
  • Self Serve Advertising Portal - Buy Ads Now! No Contracts!
  • How To Self Record An Interview and Presentations
  • Schedule A Remote Interview!
  • Check Out Our Blog
  • Advertising Specifications
  • Publisher Calendar

  • Mobile
  • Connect Mobile App

  • Audio and Video
  • Videos
  • Audio

  • Channels
  • Browse Channels

  • Categories
  • Acute Lymphoblastic Leukemia 5616
  • Acute Myelogenous Leukemia 277
  • Bladder 111
  • Bone Metastases 7
  • Brain 90
  • Breast 585
  • Business Management 5
  • Cervical 18
  • Chronic Lymphocytic Leukemia 216
  • Chronic Myelogenous Leukemia 54
  • Colorectal 184
  • Conference Coverage 1
  • COVID-19 43
  • Gastrointestinal 182
  • General 350
  • Genitourinary 6
  • Head and Neck 125
  • Help 3
  • Hematologic Malignancies 213
  • Hodgkin Lymphoma 34
  • Imaging 2
  • Immunotherapy 182
  • Kidney 399
  • Liver 41
  • Lung 108
  • Lymphoma 247
  • Melanoma and Skin 111
  • Multiple Myeloma 545
  • Myeloproliferative Disease 41
  • News 152
  • Non-Hodgkin Lymphoma 82
  • Non-Small Cell Lung Cancer 638
  • Other 525
  • Ovarian 67
  • Pancreatic 112
  • Patient Resources 51
  • Pediatric 7
  • Prostate 306
  • Sarcoma 15
  • Sickle Cell 22
  • Small Cell Lung Cancer 83
  • Supportive Care 51
  • Testicular 3
  • Urology 16
  • Uterine 10

  • Install
  • Play a Link
  • About
  • Contact
Podcast - Prof. Jonathan Ledermann @jaledermann @uclcancer @ucl #ESMO #EpithelialOvarianCarcinoma #OvarianCancer #Cancer #Research Newly Diagnosed Epithelial Ovarian Carcinoma Treatment R...
0:09:13

Podcast - Prof. Jonathan Ledermann @jaledermann @uclcancer @ucl #ESMO #EpithelialOvarianCarcinoma #OvarianCancer #Can...

Prof. Jonathan Ledermann from the UCL Cancer Institute, University College London speaks about eUpdate – Newly Diagnosed Epithelial Ovarian Carcinoma Treatment Recommendations.

Link to Abstract:
https://www.esmo.org/guidelines/gynaecological-cancers/newly-diagnosed-and-relapsed-epithelial-ovarian-carcinoma/eupdate-newly-diagnosed-epithelial-ovarian-carcinoma-treatment-recommendations?hit=mail-op

Maintenance therapy with the poly-adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitors olaparib or niraparib after surgery and chemotaxis was investigated in three phase III trials (SOLO-1, PAOLA-1/ENGOT-ov25, and PRIMA/ENGOT-OV26) in newly diagnosed high-grade epithelial ovarian cancers (including fallopian tube and peritoneal) (PFS).

SOLO1 looked at first-line maintenance monotherapy with olaparib for two years in women with FIGO stage III-IV ovarian cancer and a BRCA mutation who had a partial or complete response to platinum-based ChT.2 The primary findings showed that maintenance with olaparib reduced the risk of disease progression by 70%. (HR 0.33, 95 percent CI 0.25-0.43). Both the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) have authorized olaparib as maintenance treatment in BRCA-mutated patients in initial remission after platinum-based therapy after 5 years.6


Patients with stage III-IV ovarian cancer and no residual disease after primary debulking surgery were excluded from PRIMA/ENGOT-OV26, which evaluated niraparib as maintenance therapy for up to 3 years in patients with a high risk of treatment failure, with or without BRCA mutation.3 Patients with stage III ovarian cancer and no residual disease after primary debulking surgery were excluded, and 67 percent of patients had received neoadjuvant ChT. The Myriad myChoice test was used to stratify patients based on the tumor's homologous recombination repair deficit (HRD) (defined as an HRD score of 42 or higher). The HRD population was analyzed first, followed by the all-comer population in a hierarchical order. The HRD group (HR 0.43, 95 percent CI 0.31-0.59, P0.001) and the general population (HR 0.62, 95 percent CI 0.50-0.76, P0.001) both exhibited a substantial increase in PFS. An exploratory subgroup study revealed that women with a BRCA mutation benefited the most, whereas BRCA wild-type women with HRD benefited significantly but less. The median PFS in the HRD-negative, also known as homologous recombination proficient (HRP) group increased by 2.7 months (HR 0.68, 95 percent CI 0.49-0.94, P=0.020). Niraparib has been authorized by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) as a maintenance treatment for unselected patients in initial remission after platinum-based therapy.


Patients with stage III-IV ovarian cancer, with or without residual tumor after surgery, were treated with ChT and bevacizumab in the PAOLA-1/ENGOT-ov25 trial, and after ChT were randomly assigned to maintenance therapy with olaparib tablets or placebo for two years, as well as completing 15 months of bevacizumab in both arms of the trial.4 The tumor BRCA mutation status and response to first-line therapy were used to stratify the randomization to olaparib or placebo. The primary analysis in the all-comer intention-to-treat (ITT) population revealed a significant improvement in PFS in patients receiving olaparib and bevacizumab, with a median PFS of 22.1 months compared to 16.6 months in patients receiving placebo and bevacizumab (HR 0.59, 95 percent CI 0.49-0.72, P0.001). HRD-positive women (defined using the Myriad myChoice assay as an HRD score of 42 or higher) -including women with BRCA mutation (HR 0.33, 95 percent CI 0.25-0.45) and HRD-positive women with BRCA wild-type (HR 0.33, 95 percent CI 0.25-0.45) -had the greatest benefit (HR 0.31, 95 percent CI 0.20-0.47). (HR 0.43, 95 percent CI 0.28-0.66). The HRD-negative/unknown population showed no benefit.4 Olaparib has been authorized by the EMA and FDA as maintenance treatment in BRCA mutant and HRD patients in initial remission after platinum-based therapy in conjunction with bevacizumab.


In the VELIA/GOG-3005 trial, standard ChT was compared to veliparib given during ChT and then as maintenance for up to 2 years, or veliparib gave only with ChT.5 A hierarchical testing analysis revealed a 56 percent reduction in the risk of progression or death among patients with a BRCA mutation (HR 0.44, 95 percent CI 0.28-0.68, P0.001). In the ITT group, the median PFS was 23.5 months, while in the veliparib and control groups, it was 17.3 months. Veliparib has not been filed for regulatory clearance as a first-line treatment.


In the first-line setting, all trials have shown a benefit in median PFS for PARP inhibitor maintenance therapy, with the greatest effect seen in women with a BRCA mutation.2-6 However, it is unclear to what extent later use of PARP inhibitors in the placebo arm will affect overall survival (OS), emphasizing the importance of uncensored OS evaluation as the studies progress.


In women with a BRCA mutation, olaparib monotherapy maintenance after first-line treatment is approved. It is also approved in several countries in combination with bevacizumab in a larger group for HRD tumors (BRCA mutation or BRCA wild type). Niraparib has also been licensed as a single agent in several countries for women with stage III-IV ovarian cancer who have responded to first-line treatment, regardless of biomarker status. In most individuals, the side effects of oral PARP inhibitors are tolerable, although there is a small increase in uncommon significant adverse events such as Acute Myeloid Leukemia/Myelodysplasia. Long-term survival statistics are not yet available; this will help decision-making regarding whether subgroups of patients benefit more from PARP inhibitors as a first-line treatment or as a recurrence treatment.

2 Views
2 years Ago
ESMO
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Ovarian

Niraparib Treatment in Patients With Advanced Ovarian Cancer
0:14:45
Niraparib Treatment in Patients With Advanced Ovarian Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
72 Views
Oncology Conferences
3 weeks Ago
Ovarian Cancer Treatment: What to Watch for In New and Novel Trials Shannon Westin MD
Ovarian Cancer Treatment: What to Watch for In New and Novel Trials Shannon Westin MD
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
32 Views
Shannon Westin, MD, MPH
4 months Ago
SOLO-1 Phase 3 [2022]: Newly Diagnosed Advanced Ovarian Cancer
0:12:09
SOLO-1 Phase 3 [2022]: Newly Diagnosed Advanced Ovarian Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
760 Views
Cancer News
1 year Ago
Podcast Rebecca S. Kristeleit, MD @RKristeleit @GSTTresearch #ASCO22 #OncoTwitter Phase III ATHENA-MONO ASCO Late Breaker
0:08:11
Podcast Rebecca S. Kristeleit, MD @RKristeleit @GSTTresearch #ASCO22 #OncoTwitter Phase III ATHENA-MONO ASCO Late Bre...
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
7 Views
Annual Meeting
1 year Ago
Rebecca S. Kristeleit, MD @RKristeleit @GSTTresearch #ASCO22 #OncoTwitter Phase III ATHENA-MONO ASCO Late Breaker
0:08:11
Rebecca S. Kristeleit, MD @RKristeleit @GSTTresearch #ASCO22 #OncoTwitter Phase III ATHENA-MONO ASCO Late Breaker
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
86 Views
Annual Meeting
1 year Ago
Podcast Nicole James, PhD @BrownUniversity @womenandinfants #EOC Prognostic Immunologic Signatures In EOC
0:05:13
Podcast Nicole James, PhD @BrownUniversity @womenandinfants #EOC Prognostic Immunologic Signatures In EOC
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
11 Views
Cancer News
1 year Ago
Nicole James, PhD @BrownUniversity @womenandinfants #EOC Prognostic Immunologic Signatures In EOC
0:05:13
Nicole James, PhD @BrownUniversity @womenandinfants #EOC Prognostic Immunologic Signatures In EOC
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
96 Views
Cancer News
1 year Ago
Podcast Rebecca S. Kristeleit, MD @RKristeleit @GSTTresearch #ATHENA #OC Phase III ATHENA-MONO Trial
0:08:26
Podcast Rebecca S. Kristeleit, MD @RKristeleit @GSTTresearch #ATHENA #OC Phase III ATHENA-MONO Trial
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
38 Views
Cancer News
1 year Ago
Rebecca S. Kristeleit, MD @RKristeleit @GSTTresearch #ATHENA #OC Phase III ATHENA-MONO Trial
0:08:26
Rebecca S. Kristeleit, MD @RKristeleit @GSTTresearch #ATHENA #OC Phase III ATHENA-MONO Trial
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
121 Views
Cancer News
1 year Ago
Podcast Bradley J. Monk, MD @GOG #ATHENAMONO #OC ATHENA-MONO Phase III Trial
0:08:07
Podcast Bradley J. Monk, MD @GOG #ATHENAMONO #OC ATHENA-MONO Phase III Trial
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
71 Views
Cancer News
1 year Ago
Bradley J. Monk, MD @GOG #ATHENAMONO #OC ATHENA-MONO Phase III Trial
0:08:07
Bradley J. Monk, MD @GOG #ATHENAMONO #OC ATHENA-MONO Phase III Trial
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
87 Views
Cancer News
1 year Ago
Podcast - Oliver Dorigo, MD @Stanford @StanfordCancer @imv_inc #ASCOPubs #ESMO2021 #OvarianCancer #Cancer #Research DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer and the upd...
0:12:35
Podcast - Oliver Dorigo, MD @Stanford @StanfordCancer @imv_inc #ASCOPubs #ESMO2021 #OvarianCancer #Cancer #Research D...
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
72 Views
Cancer News
1 year Ago

comments@oncologytube.com Copyright 2023 Medicus Networks, Inc. 45121 Morgan Heights Rd. Temecula, CA 92592 - 1 (951) 944-2173